📰 9 sources covering this story

AstraZeneca hit by lung cancer drug setback: Pharma giant halts trials of experimental Volrustomig treatment

First covered 15 hrs ago · latest take 40 mins ago. Compare how each outlet is covering it — and rate the sources you trust.

Astra said its Volrustomig treatment, when combined with chemotherapy, was unlikely to help lung cancer patients live longer than rival offerings.

The trial being halted comes as another blow to the pharmaceutical company

Europe pulls Tavneos over trial integrity concerns, pricing concerns over AstraZeneca's hypertension drug, and more biotech news from The Readout

AstraZeneca Ends Phase 3 Lung Cancer Drug Trial After Review WSJ

The Times13 hrs ago

AstraZeneca posts two wins and a setback for lung cancer pipeline The Times

The FTSE 100 firm stopped a stage volrustomig drug trial a month after halting a trial for a new heart disease treatment.

The FTSE 100 firm stopped a stage volrustomig drug trial a month after halting a trial for a new heart disease treatment.

Reuters🏁 first to report15 hrs ago

AstraZeneca to discontinue late-stage lung cancer trial for volrustomig Reuters